Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
BRISBANE, Calif., March 08, 2016 -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced the receipt of positive coverage from TRICARE® National Insurance for AlloMap®.
As a part of the military health system, TRICARE is the health care program for active and returned service members and their dependents. TRICARE has over 9 million lives covered in their programs. This positive coverage decision applies to all TRICARE regions and offers retroactive coverage of AlloMap from February 2015 onwards.
“The positive coverage decision for AlloMap by TRICARE is deserved by individuals in the military and their beneficiaries who are heart transplant patients,” said Jim Yee, MD PhD, Chief Medical Officer. “Our military service population who are covered by TRICARE will now have the same access that is available through non-military health plans. We hope that this decision will ensure that patients covered by TRICARE will no longer have barriers to access AlloMap testing services.”
About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients. The company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate/severe acute cellular rejection. CareDx is also pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure, its next-generation sequencing–based test to detect donor-derived cell-free DNA after transplantation. For more information, please visit: www.CareDx.com
Media Contacts – CareDx Molly Martell, Senior Director, Marketing T: +1 415-728-6307 E: [email protected] Media Contacts - Investor Jamar Ismail, Vice President Westwicke Partners, LLC T: +1 650-996-8777 E: [email protected]
